Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totaling 751,721 shares, an increase of 4,565.6% from the April 15th total of 16,112 shares. Currently, 44.5% of the company’s stock are short sold. Based on an average daily volume of 627,214 shares, the short-interest ratio is presently 1.2 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Trading Down 3.3%

Shares of SNOA traded down $0.04 during midday trading on Monday, reaching $1.16. The stock had a trading volume of 91,709 shares, compared to its average volume of 116,580. The firm has a 50 day simple moving average of $2.20 and a 200-day simple moving average of $3.00. Sonoma Pharmaceuticals has a one year low of $0.85 and a one year high of $6.92. The firm has a market cap of $2.01 million, a PE ratio of -0.57 and a beta of 1.28.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its earnings results on Tuesday, February 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.06). The company had revenue of $4.35 million for the quarter, compared to the consensus estimate of $5.47 million. Sonoma Pharmaceuticals had a negative return on equity of 42.56% and a negative net margin of 19.04%.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. acquired a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned approximately 0.66% of Sonoma Pharmaceuticals as of its most recent SEC filing. Institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.